Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular Lymphoma
September 28th 2023Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.
Read More
Utilizing CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
February 20th 2023Wrapping up their discussion, Loretta J. Nastoupil, MD, and Marc S. Hoffman, MD, look at the use of CAR T-cell therapy for patients with mantle cell lymphoma, a rare subtype of non-Hodgkin’s lymphoma.
Read More
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
February 7th 2023Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.
Read More
Currently Available Treatment Options for Patients With R/R DLBCL
January 23rd 2023Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.
Read More